DG McDevitt

2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary

Cardiovascular and Metabolic Alterations in Mice Lacking Both β1- and β2-Adrenergic Receptors

β3-Adrenoceptors in the cardiovascular system

Beta₃‐adrenoceptors in the cardiovascular system

Tetrahydroisoquinoline derivatives containing a benzenesulfonamide moiety as potent, selective human β3 adrenergic receptor agonists

The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study

Magnesium

Functional beta3-adrenoceptor in the human heart.

Skeletal muscle hypertrophy and anti‐atrophy effects of clenbuterol are mediated by the β2‐adrenergic receptor

Magnesium and cardiovascular disease

Solid-Phase Intramolecular N-Acyliminium Pictet−Spengler Reactions as Crossroads to Scaffold Diversity

2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation

Myocyte Adrenoceptor Signaling Pathways

Functional Consequences of Altering Myocardial Adrenergic Receptor Signaling

Alterations in dynamic heart rate control in the β₁-adrenergic receptor knockout mouse

2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation

Augmentation of Cardiac Contractility Mediated by the Human β ₃ -Adrenergic Receptor Overexpressed in the Hearts of Transgenic Mice

Molecular Mechanisms of Myocardial Remodeling

The PDZ-binding motif of the β ₂ -adrenoceptor is essential for physiologic signaling and trafficking in cardiac myocytes

INSIGHTS FROM IN VIVO MODIFICATION OF ADRENERGIC RECEPTOR GENE EXPRESSION

Magnesium deficiency may be an important determinant of ventricular ectopy in digitalised patients with chronic atrial fibrillation.

Factors affecting the clinical response to treatment with digoxin and two calcium antagonists in patients with atrial fibrillation.

Cardiac effects of the beta 3‐adrenoceptor agonist BRL35135 in man.